ISIS 104838 sodium

ISIS 104838 sodium 是一种靶向 TNF-α 的反义寡核苷酸,它通过 Watson-Crick 碱基配对与人 TNF-α mRNA 特异性结合,形成 DNA:RNA 杂交双链,从而招募细胞内普遍存在的 RNase H 酶降解靶标 mRNA,从转录水平抑制 TNF-α 蛋白的合成,并在食蟹猴中引起中度、可自我限制的血小板减少,因此可用于研究炎症性疾病。
ISIS 104838 sodium
产品编号: MS-S47989 纯度: 96.37% 分子量: 7283.9 (free acid)
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

ISIS 104838 sodium 是一种靶向 TNF-α 的反义寡核苷酸,它通过 Watson-Crick 碱基配对与人 TNF-α mRNA 特异性结合,形成 DNA:RNA 杂交双链,从而招募细胞内普遍存在的 RNase H 酶降解靶标 mRNA,从转录水平抑制 TNF-α 蛋白的合成,并在食蟹猴中引起中度、可自我限制的血小板减少,因此可用于研究炎症性疾病。

生物实验数据

生物活性 ISIS 104838 sodium is an antisense oligonucleotide targeting TNF-α that specifically binds to human TNF-α mRNA through Watson-Crick base pairing to form a DNA:RNA hybrid duplex, thereby recruiting the ubiquitous intracellular RNase H enzyme to degrade the target mRNA and inhibit TNF-α protein synthesis at the transcriptional level, and it induces moderate, self-limiting thrombocytopenia in cynomolgus monkeys, so it can be used for studying inflammatory diseases.
体外研究
(In Vitro)

ISIS 104838 (30-300 nM, 6 h) sodium 可强效抑制 PMA 激活的人新生儿表皮角质形成细胞中 TNF-α 蛋白的产生,在 300 nM 浓度下可将其分泌水平降至基线的 15%。
ISIS 104838 (1-30 μM, 7 h) sodium 可强效且选择性地抑制 LPS 激活的人 THP-1 单核细胞中的 TNF-α mRNA,其 IC50 值 < 1 μM。

ELISA Assay

Cell Line: neonatal human epidermal keratinocytes (PMA-activated)
Concentration: 30, 100 and 300 nM
Incubation Time: 4 h pretreatment; 12 h PMA activation
Result: Reduced secreted TNF-α protein levels to 15% of the levels produced in the absence of oligonucleotide, representing 85% suppression of TNF-α protein at 300 nM.

Real Time qPCR

Cell Line: human THP-1 monocytic cells (LPS-activated)
Concentration: 1, 3, 10 and 30 μM
Incubation Time: 5 h recovery; 2 h LPS activation
Result: Inhibited TNF-α mRNA with an IC50 value < 1 μM, reducing TNF-α mRNA levels to < 10% of untreated levels at tested concentrations.
Showed no suppression of IL-1β mRNA levels, confirming target specificity.
体内研究
(In Vivo)

ISIS 104838 (30 mg/kg,皮下注射;每周 1-2 次,共 80 天) sodium 可在食蟹猴中通过增加血小板在肝脏和脾脏中的滞留,诱导剂量依赖性、自限性 (表型 1) 或重度 (表型 2) 血小板减少症。

Animal Model: Chinese origin (female, 4-6 years old)
Dosage: 30 mg/kg (loading dose on Days 1,4,7); 30 mg/kg twice weekly (Days 10-35); 30 mg/kg once weekly (Days 38-80); total weekly dose of 60 mg/kg
Administration: s.c.; loading dose on Days 1, 4, 7; twice weekly from Days 10 to 35; once weekly from Days 38 to 80
Result: Reduced platelet counts relative to baseline by Day 30 (baseline: 396-551 ×103 cells/μL).
Induced moderate 50% platelet count decrease (to ~150 ×103 cells/μL, Phenotype 1) in four monkeys and severe thrombocytopenia (as low as 16 ×103 cells/μL, Phenotype 2) in one monkey.
Increased mean platelet volume most significantly in the severely affected monkey.
Increased platelet sequestration in the liver and/or spleen by 25-45% relative to baseline at Day 55/56.
Increased total serum IgM by 2-4.5-fold, anti-platelet factor 4 (PF4) IgM by 2-5-fold, and anti-platelet IgM by 2-3-fold in all monkeys.
Increased monocyte chemoattractant protein 1 (MCP-1) levels by 2-9-fold and monocyte-derived extracellular vesicles by 2-6-fold in all monkeys.
Increased von Willebrand factor (VWF) antigen by 2-3-fold in all monkeys with no clear decrease in ADAMTS13 activity.
Showed correlation between IL-8 levels and platelet counts, with IL-8 levels decreasing parallel to platelet count reductions and rebounding as platelet counts recovered in the severely affected monkey.
Normalized platelet counts and mean platelet volume in the severely affected monkey after corticosteroid treatment, but had little effect in the four monkeys with moderate thrombocytopenia.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 7283.9 (free acid)

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础